Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 4/20 | 0.51 |
| ▸ | REN | P00797 | 4/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.51 |
| ▸ | F2 | P00734 | 4/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565601 | 0.93 | CALCR (0.57) | AGTR1AGTR2CALCRREN | |
| SCHEMBL30565598 | 0.93 | CALCR (0.57) | AGTR1AGTR2CALCRREN | |
| SCHEMBL30565599 | 0.92 | AGTR1 (0.59) | AGTR1AGTR2CALCRREN | |
| SCHEMBL30565596 | 0.92 | AGTR1 (0.59) | AGTR1AGTR2CALCRREN | |
| SCHEMBL30565593 | 0.90 | CALCRL (0.59) | AGTR1AGTR2SLC6A2CALCRREN | |
| SCHEMBL30368139 | 0.86 | REN (0.53) | AGTR1AGTR2SLC6A2RENF2 | |
| SCHEMBL31691539 | 0.86 | APLNR (0.61) | AGTR1AGTR2CALCRF2 | |
| SCHEMBL30785945 | 0.86 | SLC6A2 (0.61) | AGTR1AGTR2SLC6A2RENCALCRL | |
| SCHEMBL31691514 | 0.84 | APLNR (0.62) | CALCRF2 | |
| SCHEMBL31462347 | 0.84 | CALCR (0.56) | AGTR1AGTR2CALCRRENF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209024-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | AGTR1 1845/4885AGTR2 1856/4885SLC6A2 3839/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | AGTR1 1845/4885AGTR2 1856/4885SLC6A2 3839/4885 |
| US-20250304624-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | AGTR1 1845/4885AGTR2 1856/4885SLC6A2 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.